Introduction
============

Lung cancer is the most frequently diagnosed cancer and was reported in 2015 as the leading cause of cancer-associated mortalities globally, as its incidence and mortality rate have been increasing in numerous countries, including China ([@b1-ol-0-0-9559]). Of the lung cancer instances, \~80% are non-small cell lung cancer types (NSCLC), which are clinically and pathologically different from SCLC types ([@b2-ol-0-0-9559]). Treatment options for lung cancer include surgery, radiation therapy, chemotherapy and targeted therapy. Therapeutic modalities depend on a number of factors, including the type and stage of cancer ([@b3-ol-0-0-9559]). Despite ongoing therapeutic efforts, patients with lung cancer have a poor prognosis with an arithmetic average 5-year survival rate of 15% ([@b4-ol-0-0-9559]). This is primarily due to inadequate knowledge regarding tumor progression and its associated molecular alterations, which delay diagnosis ([@b5-ol-0-0-9559]); therefore, improvements in molecular genetics diagnosis and prediction of prognosis for targeted treatments and clinical decisions are required.

microRNAs (miRNAs) are a class of non-coding single stranded RNA molecules of \~22 nucleotides, which are encoded by endogenous genes ([@b6-ol-0-0-9559]). miRNAs are important regulators of gene expression in plants and animals ([@b7-ol-0-0-9559]). Recent studies have determined that miRNAs are associated with the formation and suppression of tumors ([@b8-ol-0-0-9559]--[@b10-ol-0-0-9559]). Changes in miRNA expression may serve an essential role in tumorigenesis and cancer inhibition. A number of miRNAs act as tumor suppressors, while others stimulate tumor growth. For example, there is reduced miR-143 expression in patients with colorectal cancer ([@b11-ol-0-0-9559]), miR-15-a and miR-16-1 are reduced in patients with B cell chronic lymphocytic leukemia ([@b12-ol-0-0-9559]), precursor miR-155 is highly expressed in Burkitt lymphoma, and the miR-17/92 cluster has been determined to be highly expressed in lung cancer, particularly in patients with SCLC ([@b13-ol-0-0-9559],[@b14-ol-0-0-9559]). Additionally, miR-608 regulates apoptosis in human lung cancer via the regulation of AKT serine/threonine kinase (Akt)2, and miR-99a suppresses the invasion and migration of NSCLC cells ([@b15-ol-0-0-9559]). miR-101-3p is a member of the miR-101 family, and a recent study indicated that it has tumor suppressor effects in patients with NSCLC ([@b16-ol-0-0-9559]). However, to the best of our knowledge, a limited number of studies have addressed the association between miR-101-3p and adjuvant chemotherapy in patients with NSCLC ([@b17-ol-0-0-9559]--[@b19-ol-0-0-9559]).

In the present study, the miR-101-3p expression was investigated using the Gene Expression Omnibus (GEO) database and the expression levels of miR-101-3p in NSCLC tissues was evaluated using quantitative polymerase chain reaction (qPCR). Additionally, the association between miR-101-3p and prognosis following adjuvant chemotherapy was investigated in patients with NSCLC.

Materials and methods
=====================

### Compliance with ethical standards

The present study was approved by the Ethics Committee of Shanghai Tenth People\'s Hospital, Tongji University School of Medicine (approval no. SHSY-IEC-pap-15-18; Shanghai, China). Each participant provided signed informed consent prior to participate in the present study. Patients or their legal surrogates provided signed informed consent for the surgical procedures. All specimens were handled and anonymized according to ethical and legal standards.

### miRNA expression in NSCLC from the GEO database

The expression levels of miRNAs were assessed in NSCLC tissues and normal tissue samples from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>) ([@b20-ol-0-0-9559]--[@b23-ol-0-0-9559]) using the following keywords: 'Homo sapiens'; 'NSCLC' and 'miRNA'. All datasets used the Illumina or Agilent Array platform to detect signals. For quality control, exclusion criteria for probes were as follows: i) had a low bead count of \<3 in at least 5% of samples and ii) indicated a detection-P\>0.05 in at least 5% of samples ([@b20-ol-0-0-9559]). The raw data set GSE61741 ([@b21-ol-0-0-9559]) was downloaded, which provided the peripheral blood miRNA profiles from 94 healthy controls and 73 patients with lung cancer. Additionally, GSE24709 ([@b22-ol-0-0-9559]) (including 19 healthy controls and 28 patients with lung cancer) and GSE56036 ([@b23-ol-0-0-9559]) (including 29 health controls and 23 patients with NSCLC) were downloaded in the GEO datasets to identify differentially expressed miRNAs in NSCLC samples and adjacent non-tumor tissues. Fold change (FC ≥2) and P\<0.05 served as basic screening parameters. Hierarchical clustering was performed using the multiple experiment viewer 4.7.1 software programs (<http://www.tm4.org/>).

### Clinical specimens

A total of 327 lung cancer tissues were collected from 206 male patients and 121 female patients with lung cancer who underwent surgery in Shanghai Tenth People\'s Hospital of the Tongji University School of Medicine (Shanghai, China) between January 2004 and December 2016. Inclusion criteria consisted of the following: ≤75 years with histologically proven NSCLC; no severe major organ dysfunction; World Health Organization (WHO) performance status of 0 or 1 and no prior cancer chemotherapy. Exclusion criteria consisted of the following: Age ≥76; severe major organ dysfunction; WHO performance status of \>1 or prior cancer chemotherapy. Clinical information of the patients were recorded, including sex, age, smoking history, the diameter and differentiation of the tumor, lymph node metastasis, stage of Tumor-Node-Metastasis (TNM), histological grade, degree of invasion of the lung membrane, degree of vascular invasion, whether chemotherapy had been administered, overall survival (OS) rate, disease-free survival (DFS) rate and miR-101-3p expression status. Each participant provided signed informed consent prior to participation in the present study. Patients or their legal surrogates provided signed informed consent for the surgical procedures.

### RNA extraction and detection of miR-101-3p expression by qPCR

RNA, including miRNAs, from NSCLC and normal tissue samples, were extracted using TRIzol^®^ reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer\'s protocols and an optimized protocol ([@b13-ol-0-0-9559]). RNA concentration was measured using NanoDrop ND-1000 (Thermo Fisher Scientific, Inc.) and the quality was assessed using electrophoresis in 1.5% denaturing agarose gels and viewed on a Kodak Gel Logic 2200 imaging system (Kodak, Rochester, NY, USA). TaqMan probe-based qPCR was carried out using a commercial kit (cat. no., A25576; Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the protocol of the manufacturer ([@b24-ol-0-0-9559]). RT reactions were performed using AMV Reverse Transcriptase (Takara Biotechnology Co., Ltd., Dalian, China) and qPCR was performed using a standard TaqMan PCR kit protocol on the Applied Biosystems 7900HT Sequence Detection system (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocols. qPCR for miR-101-3p was executed using the TaqMan^®^ universal PCR kit (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocols. Thermocycling conditions were as follows: Initial denaturation at 94°C for 10 min, followed by 35 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec, with a final extension at 72°C for 10 min. Each reaction was independently tested in duplicate at a minimum of three times. The following primers were used: miR-101-3p, forward, 5′-GGTCACTAAGGCGGT-3′ and reverse, 5′-CAGTCGTTGCGTCGGAGT-3′; U6, forward, 5′-CTGGTTAGTACTTGGACGGGAGAC-3′ and reverse, 5′-GTGCAGGGTCCGAGGT-3′. U6 was used as the endogenous control and the 2^−ΔΔCq^ method was used to analyze expression levels ([@b25-ol-0-0-9559]).

### Statistical analysis

Expression levels of miR-101-3p were summarized and presented as the mean ± standard deviation. All statistical analyses were performed with IBM SPSS statistics software version 20.0 for Windows (IBM Corp., Armonk, NY, USA). The paired Student\'s t-test was used to determine the difference between two groups of data. The χ^2^ test was used to evaluate the differences among groups. Kaplan-Meier estimator curves and the log-rank test were performed to analyze the OS or DFS of patients with NSCLC. Hierarchical clustering was performed using the multiple experiment viewer 4.7.1 software programs: (<http://www.tm4.org/mev/>), according to the manufacturer\'s protocols. Univariate and multivariate Cox proportional hazards regression models were used to investigate the multiple characteristics associated with the prognosis of patients with NSCLC. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression of miR-101-3p using the GEO database and clustering analysis

Firstly, miR-101-3p expression analysis was performed using data from the GEO database. GSE24709 included the miRNA profile in peripheral blood samples from patients with lung diseases and healthy controls. The present analysis demonstrated that miR-101-3p expression in NSCLC tissues was significantly reduced, compared with non-tumor tissue (FC, 1.5; P\<0.00001; [Fig. 1A and B](#f1-ol-0-0-9559){ref-type="fig"}). The miR-101-3p expression was validated in NSCLC tissues in two datasets (GSE56036 and GSE61741) and indicated that miR-101-3p levels were significantly reduced in NSCLC tissues, compared with normal tissues (P=0.005, [Fig. 1C](#f1-ol-0-0-9559){ref-type="fig"}; P=0.009, [Fig. 1D](#f1-ol-0-0-9559){ref-type="fig"}).

### miR-101-3p expression in NSCLC and adjacent non-tumor tissues

Expression of miR-101-3p was evaluated in NSCLC samples (n=327) and compared with adjacent non-tumor tissue (n=42) by qPCR. The present results indicated that miR-101-3p expression levels were significantly reduced in NSCLC tissues, compared with adjacent non-tumor tissues (FC, 0.36; P=0.002; [Fig. 2A](#f2-ol-0-0-9559){ref-type="fig"}). The level of miR-101-3p expression was 0.72±0.04 in 327 NSCLC tissues, which was significantly reduced compared with normal tissues (n=42; 1.28±0.16) (FC, 0.56; P=0.117; [Fig. 2B](#f2-ol-0-0-9559){ref-type="fig"}).

### Association between clinical characteristics and miR-101-3p expression

Additionally, miR-101-3p expression was analyzed in NSCLC samples based on various clinical characteristics, including age, sex, smoking history, lymph node metastasis, tumor differentiation, histology, TNM stage, invasion of lung membrane, vascular invasion and tumor diameter. Univariate analysis demonstrated that miR-101-3p expression was significantly associated with lymph node metastasis (P=0.08), tumor diameter (P=0.019) and TNM stage (P=0.036) in all patients with NSCLC ([Table I](#tI-ol-0-0-9559){ref-type="table"}). However, no significant association was determined between miR-101-3p expression in NSCLC samples and age, sex, smoking history, tumor differentiation, histology, invasion of the lung membrane or vascular invasion (P\>0.05; [Table I](#tI-ol-0-0-9559){ref-type="table"}).

### Univariate analysis of prognosis based on various clinical characteristics in patients with NSCLC

To ascertain whether the prognosis of patients with NSCLC was influenced by age, sex, smoking history, lymph node metastasis, tumor differentiation, histology, TNM stage, invasion of lung membrane, vascular invasion, tumor diameter or miR-101-3p expression, univariate analysis with the Kaplan-Meier estimator method was performed. The results demonstrated that lymph node metastasis (P=0.042), TNM stage (P=0.018), tumor diameter (P=0.013) and miR-101-3p expression were significantly associated with OS (P=0.004) and DFS (P=0.001) ([Table II](#tII-ol-0-0-9559){ref-type="table"}; [Fig 2](#f2-ol-0-0-9559){ref-type="fig"}).

Univariate Cox regression analysis revealed that lymph-node metastasis \[hazard ratio (HR), 1.743; 95% confidence interval (CI), 1.191--2.421; P=0.032\], TNM stage (HR, 1.562; 95% CI, 1.124--1.962; P=0.036), tumor diameter (HR, 2.125; 95% CI, 1.563--3.346; P=0.005), chemotherapy (HR, 0.778; 95% CI, 0.469--0.968; P=0.026) and miR-101 expression (HR, 0.687; 95% CI, 0.498--0.952; P=0.003) were also positively significantly associated with a poor prognosis. No significant associations were observed for age, sex, smoking history, tumor differentiation, histology, invasion of lung membrane or vascular invasion ([Table III](#tIII-ol-0-0-9559){ref-type="table"}).

### Cox regression model analysis of prognosis based on various clinical characteristics in patients with NSCLC

To determine whether miR-101-3p expression levels, in combination with lymph-node metastasis, TNM stage or tumor diameter had prognostic value, multivariate analysis with a Cox regression model was used ([Table II](#tII-ol-0-0-9559){ref-type="table"}). This analysis also indicated that lymph node metastasis (HR, 1.924; 95% CI, 1.386--3.405; P=0.014), TNM stage (HR, 1.967; 95% CI, 1.544--2.325; P=0.018) and tumor diameter (HR, 2.869; 95% CI, 2.025--3.396; P=0.002) were significantly associated with reduced prognosis ([Table III](#tIII-ol-0-0-9559){ref-type="table"}). This analysis initially included all of the parameters that were predictive of OS in the univariate analysis of the entire study group as presented in [Table II](#tII-ol-0-0-9559){ref-type="table"} (age, sex, smoking history, lymph-node metastasis, tumor differentiation, histology, vascular invasion, tumor diameter and invasion of the lung membrane).

### Prediction of OS and DFS for patients with NSCLC based on chemotherapy alone or chemotherapy and miR-101-3p expression

There was a statistically significant association between chemotherapy and OS (27.624±3.858 vs. 31.457±2.924, respectively; P=0.012) and DFS (26.985±2.247 vs. 31.004±3.357, respectively; P=0.005) in patients with NSCLC. Chemotherapy is the primary adjuvant treatment for the majority of patients with NSCLC undergoing surgery. In the present study, it was determined that adjuvant chemotherapy and high expression of miR-101-3p increased the OS and DFS of patients (32.738±3.574 and 31.946±3.789, respectively) compared with non-therapeutic patients with low expression of miR-101-3p (25.352±2.568 and 25.004±2.876, respectively) ([Table IV](#tIV-ol-0-0-9559){ref-type="table"}). These data indicated that patients with NSCLC with a high expression of miR-101-3p may have an increased benefit from chemotherapy.

Discussion
==========

Lung cancer is the most common type of malignant tumor and was reported in 2015 as the leading cause of cancer-associated mortality worldwide ([@b26-ol-0-0-9559]). Drug resistance has remained the primary factor influencing prognosis, therefore the treatment of advanced and metastatic NSCLC remains a notable challenge ([@b27-ol-0-0-9559]). The recognition of novel biomarkers for prediction of patient response to chemotherapy and prognosis is essential for improving OS and DFS in patients with NSCLC.

As molecular biomarkers, miRNAs serve significant roles in the selection of therapeutic schedules. Their functions as tumor suppressors and oncogenes in human cancer have been previously reported ([@b28-ol-0-0-9559]). In lung cancer, miRNAs exhibit alterations in expression that predict survival and relapse ([@b29-ol-0-0-9559]). miR-101 inhibits ovarian cancer cell invasion and proliferation by downregulating the expression of suppression of cytokine signaling 2 ([@b30-ol-0-0-9559]), and also has implications in suppressing the spread of a number of tumor types, including chondrosarcoma ([@b31-ol-0-0-9559]), thyroid cancer ([@b32-ol-0-0-9559]), breast cancer ([@b33-ol-0-0-9559]) and hepatocellular carcinoma ([@b34-ol-0-0-9559]). It has been reported that miR-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2 ([@b35-ol-0-0-9559]). Additionally, low expression of miR-101 in lung cancer has been demonstrated to inhibit the invasion of lung cancer by regulating its target gene enhancer of zerte 2 polycomb repressive complex 2 subunit ([@b36-ol-0-0-9559]).

miR-101-3p is a member of the miR-101 family and inhibits the metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1)-induced activation of the phosphoinositide 3-kinase/Akt signaling pathway, resulting in the inhibition of NSCLC growth and metastasis ([@b16-ol-0-0-9559]). It is notable that miR-101-3p expression in NSCLC cells was significantly reduced, whereas MALAT-1 expression was significantly increased. Furthermore, high expression of miR-101-3p inhibits the proliferation, migration and invasion of NSCLC ([@b37-ol-0-0-9559]). In the present study, significantly reduced levels of miR-101-3p was observed in patients with NSCLC, compared with healthy controls. The level of miR-101-3p expression in NSCLC was determined to be associated with OS and DFS, indicating that miR-101-3p may serve as a prognostic biomarker in patients with NSCLC. The analysis of a number of clinical factors, including tumor diameter, TNM stage and lymph node metastasis, demonstrated associations with OS and DFS. Notably, as an independent parameter, miR-101-3p expression levels in NSCLC also affected prognosis and survival.

miR-101-3p is a valuable prognostic predictor and therapeutic target of clinical chemotherapy. The present analysis determined that a high level of expression of miR-101-3p in patients with NSCLC who had undergone routine chemotherapy was positively associated with OS and DFS rates. This indicated that patients with NSCLC with high levels of miR-101-3p expression may have improved benefit from chemotherapy. In brief, miR-101-3p was significantly downregulated in NSCLC, which increased the OS and DFS rates of patients receiving adjuvant chemotherapy. Based on these results, whether the miR-101-3p expression level may serve as a biomarker for chemotherapy use in patients with NSCLC should be investigated, and therefore may be a valuable and promising biomarker for this disease. However, the molecular and pathophysiological mechanisms of miR-101-3p in NSCLC are not fully understood, and will be assessed in subsequent studies. The present study had a number of limitations. For example, this is a retrospective study and only one marker was addressed. There are other markers or associated pathways that must be studied. In the future, multicenter studies regarding miR-101-3p in NSCLC should be performed.

In conclusion, the present data confirmed that with adjuvant chemotherapeutic treatment the median OS and DFS rate of patients improved. The analyses demonstrated that low expression of miR-101-3p, together with adjuvant chemotherapy, notably improved the OS and DFS of patients with NSCLC. The use of miR-101-3p as a specific and sensitive biomarker may be suitable for prediction of therapeutic responses in patients with advanced NSCLC, which may result in a superior level of personalized therapy. Therefore, miR-101-3p may be considered as a potential biomarker for chemosensitivity in the tumors of patients with NSCLC.
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![Analysis of miR-101-3p expression in NSCLC using the GEO database. (A) Data from the GEO dataset (GSE24709) was clustered using the multiple experiment viewer 4.7.1 software. (B) The miR-101-3P expression level in normal tissues, compared with NSCLC tissues, from the GEO database (GSE24709). (C) The miR-101-3p expression level in normal tissues, compared with NSCLC tissues, from the GEO database (GSE56036). (D) The miR-101-3p expression level in normal tissues, compared with NSCLC tissues, from the GEO database (GSE61741). miR, microRNA; NSCLC, non-small cell lung cancer; GEO, Gene Expression Omnibus; FC, fold change.](ol-16-06-7048-g00){#f1-ol-0-0-9559}

![Analysis of miR-101-3p expression in NSCLC and normal lung cancer tissues via quantitative polymerase chain reaction. (A) The expression levels of miR-101-3p in 42 paired NSCLC and adjacent non-cancerous tissues. (B) The miR-101-3p expression in NSCLC (n=327) and paired adjacent non-tumor tissues (n=42) was analyzed. Univariate survival analysis of (C) OS and (D) DFS in NSCLC as determined by Kaplan-Meier plots based on miR-101-3p expression. miR, microRNA; NSCLC, non-small cell lung cancer; FC, fold change; OS, overall survival; DFS, disease-free survival.](ol-16-06-7048-g01){#f2-ol-0-0-9559}

###### 

Association between miR-101 expression and clinical characteristics.

  Factor                      No. of patients   miR-101 expression (mean ± SD)   P-value
  --------------------------- ----------------- -------------------------------- ----------------------------------------------------
  Age (years)                                                                    0.668
    ≥60                       167               0.703±0.021                      
    \<60                      160               0.728±0.059                      
  Sex                                                                            0.239
    Male                      206               0.732±0.045                      
    Female                    121               0.699±0.091                      
  Smoking history                                                                0.078
    Smoked                    136               0.682±0.028                      
    Never smoked              119               0.735±0.071                      
    Unknown                   72                0.728±0.031                      
  Lymph node metastasis                                                          0.008^[a](#tfn1-ol-0-0-9559){ref-type="table-fn"}^
    Positive                  105               0.632±0.084                      
    Negative                  166               0.753±0.054                      
    Unknown                   56                0.721±0.029                      
  Tumor differentiation                                                          0.097
    Poorly                    136               0.691±0.063                      
    Moderately                111               0.714±0.036                      
    Well                      80                0.722±0.089                      
  Histology                                                                      0.604
    Adenocarcinoma            185               0.705±0.039                      
    Squamous cell carcinoma   142               0.711±0.057                      
  TNM stage (38)                                                                 0.036^[a](#tfn1-ol-0-0-9559){ref-type="table-fn"}^
    III--IV                   158               0.681±0.067                      
    I--II                     169               0.736±0.055                      
  Invasion of lung membrane                                                      0.063
    Positive                  109               0.686±0.029                      
    Negative                  168               0.725±0.013                      
    Unknown                   50                0.721±0.066                      
  Vascular invasion                                                              0.269
    Positive                  65                0.692±0.057                      
    Negative                  189               0.721±0.033                      
    Unknown                   73                0.708±0.037                      
  Tumor diameter (cm)                                                            0.019^[a](#tfn1-ol-0-0-9559){ref-type="table-fn"}^
    ≥5                        186               0.677±0.054                      
    \<5                       141               0.743±0.065                      

P\<0.05. miR, microRNA; TNM, Tumor-Node-Metastasis; SD, standard deviation.

###### 

Univariate analysis of OS and DFS based on patients stratified by clinical characteristics.

                                      OS time   Progression-free survival time                                                                                  
  ----------------------------- ----- --------- -------------------------------- ---------------------------------------------------- -------- ---------------- ----------------------------------------------------
  Age (years)                                                                                                                                                   0.331
    ≥60                         167   28.065    26.945--30.253                   0.289                                                28.069   26.889--30.453   
    \<60                        160   29.331    28.314--31.846                                                                        29.564   28.651--31.754   
  Sex                                                                                                                                                           0.822
    Male                        206   29.652    28.773--31.325                   0.806                                                30.594   28.797--31.393   
    Female                      121   31.068    28.962--32.618                                                                        31.056   28.845--32.648   
  Smoking history                                                                                                                                               0.115
    Smoked                      136   27.849    26.152--29.086                   0.109                                                27.654   26.465--29.754   
    Never smoked                119   29.659    27.854--30.554                                                                        29.435   27.784--30.058   
    Unknown                     72    28.381    26.989--31.062                                                                        28.675   27.095--31.365   
  Lymph node metastasis                                                                                                                                         0.041^[a](#tfn2-ol-0-0-9559){ref-type="table-fn"}^
    Positive                    105   26.731    24.377--29.501                   0.042^[a](#tfn2-ol-0-0-9559){ref-type="table-fn"}^   26.456   24.943--29.063   
    Negative                    166   31.229    28.815--33.056                                                                        31.854   28.326--33.064   
    Unknown                     56    28.056    26.053--30.434                                                                        28.06    26.366--30.582   
  Tumor differentiation (38)                                                                                                                                    0.274
    Poorly                      136   28.851    26.826--31.058                   0.246                                                28.821   26.487--31.348   
    Moderately                  111   29.348    27.854--31.854                                                                        29.815   27.145--31.487   
    Well                        80    31.857    29.581--32.783                                                                        31.825   29.747--33.045   
  Histology (38)                                                                                                                                                0.867
    Adenocarcinoma              185   29.744    26.451--31.845                   0.865                                                28.745   26.787--31.165   
    Squamous cell carcinoma     142   29.043    25.624--32.434                                                                        29.257   25.474--32.345   
  TNM stage (38)                                                                                                                                                0.012^[a](#tfn2-ol-0-0-9559){ref-type="table-fn"}^
    III--IV                     158   26.748    24.285--30.647                   0.018^[a](#tfn2-ol-0-0-9559){ref-type="table-fn"}^   26.778   24.548--30.487   
    I--II                       169   31.049    28.834--34.415                                                                        32.091   28.674--34.358   
  Invasion of lung membrane                                                                                                                                     0.067
    Positive                    109   27.995    25.453--29.454                   0.086                                                27.123   25.748--29.486   
    Negative                    168   31.412    28.542--32.966                                                                        31.545   28.364--32.684   
    Unknown                     50    28.095    26.354--30.888                                                                        28.157   26.387--30.054   
  Vascular invasion                                                                                                                                             0.066
    Positive                    65    27.849    25.446--29.354                   0.072                                                27.048   25.487--29.954   
    Negative                    189   31.069    26.878--33.147                                                                        31.157   26.748--33.444   
    Unknown                     73    29.534    27.956--31.259                                                                        29.348   27.248--31.187   
  Tumor diameter (cm)                                                                                                                                           0.009^[a](#tfn2-ol-0-0-9559){ref-type="table-fn"}^
    ≥5                          186   25.386    23.685--27.913                   0.013^[a](#tfn2-ol-0-0-9559){ref-type="table-fn"}^   24.886   23.065--26.648   
    \<5                         141   31.553    27.456--33.546                                                                        30.661   28.446--32.596   
  miR-101 expression (median)                                                                                                                                   0.001^[a](#tfn2-ol-0-0-9559){ref-type="table-fn"}^
    Low                         163   24.154    22.314--26.043                   0.004^[a](#tfn2-ol-0-0-9559){ref-type="table-fn"}^   24.365   22.625--26.443   
    High                        164   32.317    28.414--34.916                                                                        33.053   28.456--34.994   

P\<0.05. miR, microRNA; TNM, Tumor-Node-Metastasis; OS, overall survival; CI, confidence interval.

###### 

Cox regression model analysis for prognosis based on various clinical characteristics in patients with NSCLC.

                              miR-101 univariate analysis   miR-101 multivariate analysis                                                                               
  --------------------------- ----------------------------- ------------------------------- ---------------------------------------------------- ------- -------------- ----------------------------------------------------
  Age                         1.153                         0.681--1.554                    0.093                                                1.176   0.699--1.568   0.087
  Sex                         0.887                         0.525--1.115                    0.801                                                0.867   0.504--1.089   0.542
  Smoking history             1.196                         0.723--1.587                    0.087                                                1.198   0.825--1.589   0.061
  Lymph-node metastasis       1.743                         1.191--2.421                    0.032^[a](#tfn3-ol-0-0-9559){ref-type="table-fn"}^   1.924   1.386--3.405   0.014^[a](#tfn3-ol-0-0-9559){ref-type="table-fn"}^
  Tumor differentiation       1.154                         0.961--1.224                    0.224                                                1.168   0.979--1.231   0.201
  Histology                   0.835                         0.698--1.142                    0.324                                                0.831   0.624--1.104   0.265
  TNM stage                   1.562                         1.124--1.962                    0.036^[a](#tfn3-ol-0-0-9559){ref-type="table-fn"}^   1.967   1.544--2.325   0.018^[a](#tfn3-ol-0-0-9559){ref-type="table-fn"}^
  Invasion of lung membrane   1.164                         1.006--1.453                    0.089                                                1.196   1.075--1.469   0.066
  Vascular invasion           1.169                         1.021--1.468                    0.088                                                1.182   1.069--1.494   0.059
  Tumor diameter              2.125                         1.563--3.346                    0.005^[a](#tfn3-ol-0-0-9559){ref-type="table-fn"}^   2.869   2.025--3.396   0.002^[a](#tfn3-ol-0-0-9559){ref-type="table-fn"}^
  Chemotherapy                0.778                         0.469--0.968                    0.026^[a](#tfn3-ol-0-0-9559){ref-type="table-fn"}^   0.559   0.374--0.786   0.006^[a](#tfn3-ol-0-0-9559){ref-type="table-fn"}^
  miR-101 expression          0.687                         0.498--0.952                    0.003^[a](#tfn3-ol-0-0-9559){ref-type="table-fn"}^                          

P\<0.05. miR, microRNA; CI, confidence interval; TNM, Tumor-Node-Metastasis.

###### 

OS and DFS of patients with NSCLC based on chemotherapy alone or chemotherapy and miR-101 expression.

                                            OS             DFS                                                      
  ----------------------------------- ----- -------------- ---------------- ------- -------------- ---------------- ---------
  Chemotherapy                                                              0.012                                   0.005
    Yes                               231   31.457±2.924   28.728--34.632           31.004±3.357   28.244--33.148   
    No                                96    27.624±3.858   25.741--29.478           26.985±2.247   25.311--28.634   
  Chemotherapy & miR-101 expression                                         0.001                                   \<0.001
    P & H                             65    32.738±3.574   30.469--34.774           31.946±3.789   28.158--33.564   
    N & L                             87    25.352±2.568   22.914--27.353           25.004±2.876   23.043--26.965   

P & H, chemotherapy and high miR-101 expression; N & L, no chemotherapy and low miR-101 expression. OS, overall survival; DFS, disease-free survival; miR, microRNA; SD, standard deviation; CI, confidence interval.

[^1]: Contributed equally
